Nissan Chemical Industries Limited

Yutaka Hirokawa

Norihisa Ishiwata

Katsuaki Miyaji

Kazufumi Yanagihara

Shunsuke Iwamoto

Shingo Owada

Yukihiro Shigeta

Takanori Nakamura

Masato Horikawa

Hirofumi Ota

Satoshi Nakano

Tsuneo Watanabe

Junji Kamon

Koji Toyama

Hiroshi Nagai

Yusuke Shintani

Kazuya Takeuchi

Kei Nagae

Megumi Io

Katsuaki Myaji

Shingo Oowada

Shunuske Iwamoto

A compound represented by the formula (1): wherein A, B, R, L, R, L, L, Y, L, Rand X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators

Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases. 

Pyridazinone compounds and P2X7 receptor inhibitors

A compound represented by the formula (1): wherein A is a nitrogen atom or CR, B is an oxygen atom, a sulfur atom or NR(provided that when A is a nitrogen atom, B is not NH), Ris a Caryl group, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, X is OR, SRor NRNR, Ris a hydrogen atom, a formyl group, a Calkyl group or the like, Lis a bond or the like, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Y is an oxygen atom, a sulfur atom or NR, and Ris a Caryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Heterocyclic compounds and thrombopoietin receptor activators

The present invention provides compounds useful for prevention, treatment or alleviation of diseases against which activation of the thrombopoietin receptor is effective. A compound represented by the formula (1): wherein A, B, R, L, R, L, L, Y, L, Rand X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Amide compound and thrombopoietin receptor activator

Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R, R, R, L, L, L, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators

A compound represented by the formula (I) (wherein R, R, Rand Rare as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Thiophene compounds and thrombopoietin receptor activators

Pyrazole compounds and thrombopoietin receptor activators

A compound represented by the formula (1): wherein A is a nitrogen atom or CR, B is an oxygen atom, a sulfur atom or NR(provided that when A is a nitrogen atom, B is not NH), Ris a Caryl group, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, X is OR, SRor NRNR, Ris a hydrogen atom, a formyl group, a Calkyl group or the like, Lis a bond or the like, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Y is an oxygen atom, a sulfur atom or NR, and Ris a Caryl group, a tautomer, prodrug or is pharmaceutically acceptable salt of the compound or a solvate thereof.

A compound represented by the formula (1): wherein A is a nitrogen atom or CR, B is an oxygen atom, a sulfur atom or NR(provided that when A is a nitrogen atom, B is not NH), Ris a Caryl group, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, X is ORSRor NRNR, Ris a hydrogen atom, a formyl group, a Calkyl group or the like, Lis a bond or the like, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Y is an oxygen atom, a sulfur atom or NR, and Ris a Caryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Growing community of inventors

Funabashi, Japan

Yutaka Hirokawa